Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Risk genes beyond APOE

Topic: Brain proteins, microglia and lab models

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that is familial in 10% of cases. We have identified a missense mutation in the gene encoding fused in sarcoma (FUS) in a British kindred, linked to ALS6. In a survey of 197 familial ALS index cases, we identified two further missense mutations in eight families. Postmortem analysis of three cases with FUS mutations showed FUS-immunoreactive cytoplasmic inclusions and predominantly lower motor neuron degeneration. Cellular expression studies revealed aberrant localization of mutant FUS protein. FUS is involved in the regulation of transcription and RNA splicing and transport, and it has functional homology to another ALS gene, TARDBP, which suggests that a common mechanism may underlie motor neuron degeneration.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Vance, C. A., Rogelj, B., Hortobágyi, T., De Vos, K. J., Nishimura, A. L., Sreedharan, J., et al. (2009). Mutations in FUS, an RNA Processing Protein, Cause Familial Amyotrophic Lateral Sclerosis Type 6. Science. https://doi.org/10.1126/science.1165942

Vancouver

Vance CA, Rogelj B, Hortobágyi T, De Vos KJ, Nishimura AL, Sreedharan J, et al. Mutations in FUS, an RNA Processing Protein, Cause Familial Amyotrophic Lateral Sclerosis Type 6. Science. 2009. doi:10.1126/science.1165942. PMID: 19251628.

BibTeX

@article{vance2009-19251628,
  author  = {Vance, Caroline A. and Rogelj, Boris and Hortobágyi, Tibor and De Vos, Kurt J. and Nishimura, Agnes Lumi and Sreedharan, Jemeen and Hu, Xun and Smith, Bradley N. and Ruddy, Deborah and Wright, Paul D. and Ganesalingam, Jeban and Williams, Kelly L. and Tripathi, Vineeta and Al‐Saraj, Safa and Al‐Chalabi, Ammar and Leigh, P. Nigel and Blair, Ian P. and Nicholson, Garth A. and de Belleroche, Jackie and Gallo, Jean‐Marc and Miller, Christopher C.J. and Shaw, Christopher E.},
  title   = {{Mutations in FUS, an RNA Processing Protein, Cause Familial Amyotrophic Lateral Sclerosis Type 6}},
  journal = {Science},
  year    = {2009},
  doi     = {10.1126/science.1165942},
  pmid    = {19251628},
  url     = {https://doi.org/10.1126/science.1165942}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 22 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Why it matters

Identified mutations in the FUS gene in families with inherited amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease. The authors suggest a mechanism shared with another ALS gene, TARDBP, may underlie motor neuron degeneration. The study is about ALS, not Alzheimer's.

How this study scored 61/100
How this study's score is builtJournal tier 10 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence left out, no data; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 7 of 7; Citations per year 5 of 5; Impact for its field and year 6 of 6; Cited by studies here 0 of 6; Still being cited 4 of 4; Senior author's track record 4 of 4; Institution's track record 1 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 58 of the 95 points it could be judged on, which is 61 of 100. Total 61 of 100.58 of the 95 points we could judge = 61 of 100

Published in a top-tier journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on strength of evidence, so that was left out: it earned 58 of the 95 points we could judge it on, which is 61 out of 100.

ComponentPointsWhy
Journal tier 10 / 10 Tier 1 — top-tier general journal (Science)
Journal's citation record 4 / 4 Science: journal h-index 1,754 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence — / 5 No evidence rating recorded — left out of this score
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2009 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 7 / 7 Cited 2,570 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 135.3 citations a year over 19 year(s) since 2009
Impact for its field and year 6 / 6 Cited 114.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 4 / 4 Cited 246 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Christopher E. Shaw: h-index 104 (OpenAlex, whole career)
Institution's track record 1 / 3 The University of Sydney: institution h-index 1,466 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 6 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 19251628)
Free to read 2 / 2 Free to read
Points 58 / 95 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 58 of the 95 points we could judge it on is 61 out of 100.
Total 61 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Related studies in Risk genes beyond APOE

Also tagged “tdp-43”

1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.

Similar studies

More on Risk genes beyond APOE

See all studies in Risk genes beyond APOE →